{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-029078","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2026-06-17T20:05:18+00:00","discovered_at":"2026-06-17T20:06:00.266520+00:00","generated_at":"2026-06-17T20:11:45.401718+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"IMDX shareholders approve equity plan amendment increasing authorized shares to 5.55M","bullets":["Shareholders voted to increase authorized shares under the 2018 equity plan by 1,750,000 to a total of 5,550,000 shares.","Four directors re-elected: Joshua Riggs, Andrew Arno, Andrew J. Last, and Louis E. Silverman.","Appointment of CBIZ CPAs P.C. as independent auditor for FY2026 ratified by shareholders.","Non-binding advisory 'say-on-pay' proposal for 2025 executive compensation approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-029078","json":"https://secwatch.observer/filing/0001493152-26-029078.json","markdown":"https://secwatch.observer/filing/0001493152-26-029078.md","text":"https://secwatch.observer/filing/0001493152-26-029078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226029078/0001493152-26-029078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226029078/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T20:11:45.401718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0afd36909ae78926c9a10f4129561b22494f02ae","claim":"Insight Molecular Diagnostics Inc. shareholders approved To approve, on a non-binding advisory basis, the Company’s named executive officer compensation for the year ended December 31, 2025 at the 2026-06-11 meeting.","evidence_excerpt":"Say On Pay Proposal Shares Non-Votes 19,199,697 26,126 19,679 4,708,719","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226029078/0001493152-26-029078-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"88e29629dd4ca75513b240fddc7506a2d4fcfb50","claim":"Insight Molecular Diagnostics Inc. shareholders approved To elect the following four (4) director nominees, each to serve until the 2027 annual meeting of shareholders and until his successor has been elected and qualified, or until his earlier death, resignation, or removal: Joshua Riggs, Andrew Arno, Andrew J. Last and Louis E. Silverman at the 2026-06-11 meeting.","evidence_excerpt":"Shares Voted Director Nominee For Against Abstained Broker Non-Votes Joshua Riggs 19,239,253 2,420 3,820 4,708,719 Andrew Arno 19,100,993 140,445 4,056 4,708,719 Andrew J. Last 19,237,621 3,938 3,935 4,708,719 Louis E. Silverman 19,224,148 17,290 4,056 4,708,719","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226029078/0001493152-26-029078-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"af069103a61cc90e41a63e40c4e517ff68a499f7","claim":"Insight Molecular Diagnostics Inc. shareholders approved To ratify the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-11 meeting.","evidence_excerpt":"Ratification of Appointment of Accounting Firm Shares Non-Votes 23,949,191 2,420 2,601 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226029078/0001493152-26-029078-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"cad4aad4069568a77ab75d36921e47b640dfc834","claim":"Insight Molecular Diagnostics Inc. shareholders approved To approve an amendment to the Amended and Restated 2018 Equity Incentive Plan to increase the total number of shares of the Company’s common stock authorized for issuance under the Incentive Plan by 1,750,000, to a total of 5,550,000 shares at the 2026-06-11 meeting.","evidence_excerpt":"Approval of Amendment to Incentive Plan Shares Non-Votes 19,117,865 122,829 4,799 4,708,719","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226029078/0001493152-26-029078-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}